- Sanner has announced a leadership change as part of its transformation into a CDMO for medical devices and complex pharmaceutical drug delivery systems.
- Stefan Verheyden will become CEO in autumn 2025, succeeding Dr. Johannis Willem van Vliet, with Heino Lennartz serving as interim CEO.
Sanner has announced a change in leadership as part of its strategic move to strengthen its position as a contract development and manufacturing organisation (CDMO) for medical devices and advanced pharmaceutical drug delivery systems.
The company confirmed that CEO Dr. Johannis Willem van Vliet will leave the role shortly. Until the appointment of a permanent successor in autumn 2025, Chairman Heino Lennartz will serve as interim CEO, drawing on his experience in the pharmaceutical and CDMO sectors to guide the transition and support the incoming leader.
Listen to our interview with Stefan Verheyden from February 2024
Stefan Verheyden will assume the role of CEO later in 2025. Holding a degree in chemistry, he has more than 30 years of experience in the pharmaceutical and biopharmaceutical industry, including expertise in primary packaging. Most recently, he served as Global Vice President Sales Pharma and Biopharma Injectables at a leading company in the primary packaging and contract manufacturing space.
“We are delighted to welcome Mr. Verheyden to the Sanner Group as an experienced CEO. His many years of expertise and reputation in the industry will be a great asset to us in both the packaging and CDMO sectors,” said Lennartz.
The company noted that under Dr. van Vliet’s leadership, Sanner completed the acquisitions of Springboard and Gilero and oversaw the ramp-up of new production sites in Bensheim, Germany, and Greensboro, USA.
